Office of Testing and Research, but now it's been placed in the immediate office of the Office of Pharmaceutical Science and the purpose for that was to increase the breadth of the types of research studies that are done and to bring also some more visibility to the types of projects that we actually do do.
Some of the projects -- I'll go into that later, but the Rapid Response Projects are in general very high-priority projects and they have a short turnaround time. We decided that a maximum of six months is what we'd like to set for the completion of the studies, and they're expected to have regulatory impact, direct regulatory impact. By that, I mean they should support reviewer recommendations, whether in the Office of New Drugs or the Office of Generic Drugs. They should support labeling changes, and they should support advisory committee issues.
Some of the examples of some of the past projects that we've done, we've done palatability studies of doxycycline and potassium iodide ‑‑ these were two separate studies ‑‑ in human subjects to identify dosing